Evidence map›Paper›PMID 40115032›Full record

ArticleJournal of translational internal medicine2025

Targeting regulated cell death: Apoptosis, necroptosis, pyroptosis, ferroptosis, and cuproptosis in anticancer immunity.

Ziyu Guo, Yihuang Liu, Danyao Chen, Yuming Sun, Daishi Li, Yu Meng, Qian Zhou, Furong Zeng, Guangtong Deng, Xiang Chen

Abstract read
In one paragraph

Article in Journal of translational internal medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers.

0numbers the graph read from it
0cells of the map it votes in
70citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

70 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Relationship between different modes of death and premature ovarian insufficiency: a literature review.Apoptosis : an international journal on programmed cell death · 2026
    Review
  17. Article
  18. Article
  19. Review
  20. Article

10 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ziyu GuoDepartment of Dermatology, Xiangya Hospital, Central South University, Changsha 410008, Hunan Province, China.
Yihuang LiuDepartment of Dermatology, Xiangya Hospital, Central South University, Changsha 410008, Hunan Province, China.
Danyao ChenDepartment of Thoracic Surgery, Xiangya Hospital, Central South University, Changsha 410008, Hunan Province, China.
Yuming SunDepartment of Oncology, Xiangya Hospital, Central South University, Changsha 410008, Hunan Province, China.
Daishi LiDepartment of Dermatology, Xiangya Hospital, Central South University, Changsha 410008, Hunan Province, China.
Yu MengDepartment of Dermatology, Xiangya Hospital, Central South University, Changsha 410008, Hunan Province, China.
Qian ZhouDepartment of Dermatology, Xiangya Hospital, Central South University, Changsha 410008, Hunan Province, China.
Furong ZengDepartment of Plastic and Cosmetic Surgery, Xiangya Hospital, Central South University, Changsha 410008, Hunan Province, China.
Guangtong DengDepartment of Dermatology, Xiangya Hospital, Central South University, Changsha 410008, Hunan Province, China.ORCID https://orcid.org/0000-0002-4424-9727
Xiang ChenDepartment of Dermatology, Xiangya Hospital, Central South University, Changsha 410008, Hunan Province, China.ORCID https://orcid.org/0000-0001-8187-636X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the evolving landscape of cancer treatment, the strategic manipulation of regulated cell death (RCD) pathways has emerged as a crucial component of effective anti-tumor immunity. Evidence suggests that tumor cells undergoing RCD can modify the immunogenicity of the tumor microenvironment (TME), potentially enhancing its ability to suppress cancer progression and metastasis. In this review, we first explore the mechanisms of apoptosis, necroptosis, pyroptosis, ferroptosis, and cuproptosis, along with the crosstalk between these cell death modalities. We then discuss how these processes activate antigen-presenting cells, facilitate the cross-priming of CD8+ T cells, and trigger anti-tumor immune responses, highlighting the complex effects of novel forms of tumor cell death on TME and tumor biology. Furthermore, we summarize potential drugs and nanoparticles that can induce or inhibit these emerging RCD pathways and their therapeutic roles in cancer treatment. Finally, we put forward existing challenges and future prospects for targeting RCD in anti-cancer immunity. Overall, this review enhances our understanding of the molecular mechanisms and biological impacts of RCD-based therapies, providing new perspectives and strategies for cancer treatment.

Indexed as

anticancer immunityapoptosiscuproptosisferroptosisnecroptosispyroptosistumor microenvironment

Identifiers

PMID40115032
PMCPMC11921819

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.